Advertisement

Respiratory Tract Diseases That May Be Mistaken for Infection

  • Robert M. Kotloff
  • Burton F. Dickey
  • Nicholas Vander ElsEmail author
Chapter

Abstract

The differential diagnosis of lung infiltrates in transplant patients includes non-infectious processes that may mimic pneumonia. Hydrostatic and non-cardiogenic pulmonary edema, as well as transfusion-related lung injury, may cause bilateral airspace opacification that may be confused with an infectious process. Chemotherapeutic agents, whether administered for treatment of an underlying hematologic malignancy, for induction prior to transplant, or for the treatment of GVHD or graft rejection after transplant, may cause lung injury that in some cases may not become apparent until years later. Radiation-induced lung injury may cause a distinct pattern of lung injury, which may present months after exposure. In hematopoietic stem cell transplant patients, pulmonary diagnoses such as engraftment syndrome, idiopathic pneumonia syndrome, and diffuse alveolar hemorrhage can mimic pneumonia. After lung transplantation, infiltrates may be seen as a consequence of primary graft dysfunction or allograft rejection. Organizing pneumonia may be seen both in recipients of solid organ and hematopoietic stem cell transplants. Organizing pneumonia may be cryptogenic or associated with the use of the mTOR inhibitor sirolimus. Failure to accurately diagnose non-infectious infiltrates may lead to unnecessary antibiotic treatment and failure to address the underlying pathophysiologic process.

Keywords

Pneumonia Pneumonitis Infiltrate Radiographic Radiologic 

References

  1. 1.
    Kotloff RM, Ahya VN, Crawford SW. Pulmonary complications of solid organ and hematopoietic stem cell transplantation. Am J Respir Crit Care Med. 2004;170(1):22–48.PubMedCrossRefPubMedCentralGoogle Scholar
  2. 2.
    Lim do H, Lee J, Lee HG, Park BB, Peck KR, Oh WS, et al. Pulmonary complications after hematopoietic stem cell transplantation. J Korean Med Sci. 2006;21(3):406–11.PubMedPubMedCentralCrossRefGoogle Scholar
  3. 3.
    Yeh ET, Bickford CL. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol. 2009;53(24):2231–47.PubMedCrossRefPubMedCentralGoogle Scholar
  4. 4.
    Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, et al. 2009 focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation. 2009;119(14):e391–479.PubMedPubMedCentralGoogle Scholar
  5. 5.
    Wilson JF. In the clinic. Heart failure. Ann Intern Med. 2007;147(11):ITC12-1-ITC-6.Google Scholar
  6. 6.
    Ware LB, Matthay MA. Clinical practice. acute pulmonary edema. N Engl J Med. 2005;353(26):2788–96.PubMedCrossRefPubMedCentralGoogle Scholar
  7. 7.
    Maeder MT, Kaye DM. Heart failure with normal left ventricular ejection fraction. J Am Coll Cardiol. 2009;53(11):905–18.PubMedCrossRefPubMedCentralGoogle Scholar
  8. 8.
    Kaplan R, Bashoura L, Shannon VR, Dickey BF, Stover DI. Noninfectious lung infiltrates that may be confused with pneumonia in the cancer patient. In: Safdar A, editor. Principles and practice of cancer infectious disease. New York: Springer; 2011. p. 153–65.CrossRefGoogle Scholar
  9. 9.
    Kollef MH, Schuster DP. The acute respiratory distress syndrome. N Engl J Med. 1995;332(1):27–37.PubMedCrossRefPubMedCentralGoogle Scholar
  10. 10.
    Piantadosi CA, Schwartz DA. The acute respiratory distress syndrome. Ann Intern Med. 2004;141(6):460–70.PubMedCrossRefGoogle Scholar
  11. 11.
    Holness L, Knippen MA, Simmons L, Lachenbruch PA. Fatalities caused by TRALI. Transfus Med Rev. 2004;18(3):184–8.PubMedCrossRefGoogle Scholar
  12. 12.
    Popovsky MA, Moore SB. Diagnostic and pathogenetic considerations in transfusion-related acute lung injury. Transfusion. 1985;25(6):573–7.PubMedCrossRefPubMedCentralGoogle Scholar
  13. 13.
    Looney MR, Gropper MA, Matthay MA. Transfusion-related acute lung injury: a review. Chest. 2004;126(1):249–58.PubMedCrossRefPubMedCentralGoogle Scholar
  14. 14.
    Spitzer TR. Engraftment syndrome following hematopoietic stem cell transplantation. Bone Marrow Transplant. 2001;27(9):893–8.PubMedCrossRefPubMedCentralGoogle Scholar
  15. 15.
    Capizzi SA, Kumar S, Huneke NE, Gertz MA, Inwards DJ, Litzow MR, et al. Peri-engraftment respiratory distress syndrome during autologous hematopoietic stem cell transplantation. Bone Marrow Transplant. 2001;27(12):1299–303.PubMedCrossRefPubMedCentralGoogle Scholar
  16. 16.
    Clark JG, Hansen JA, Hertz MI, Parkman R, Jensen L, Peavy HH. NHLBI workshop summary. Idiopathic pneumonia syndrome after bone marrow transplantation. Am Rev Respir Dis. 1993;147(6 Pt 1):1601–6.PubMedCrossRefPubMedCentralGoogle Scholar
  17. 17.
    Watkins TR, Chien JW, Crawford SW. Graft versus host-associated pulmonary disease and other idiopathic pulmonary complications after hematopoietic stem cell transplant. Semin Respir Crit Care Med. 2005;26(5):482–9.PubMedCrossRefPubMedCentralGoogle Scholar
  18. 18.
    Yanik G, Hellerstedt B, Custer J, Hutchinson R, Kwon D, Ferrara JL, et al. Etanercept (Enbrel) administration for idiopathic pneumonia syndrome after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2002;8(7):395–400.PubMedCrossRefPubMedCentralGoogle Scholar
  19. 19.
    Yanik GA, Ho VT, Levine JE, White ES, Braun T, Antin JH, et al. The impact of soluble tumor necrosis factor receptor etanercept on the treatment of idiopathic pneumonia syndrome after allogeneic hematopoietic stem cell transplantation. Blood. 2008;112(8):3073–81.PubMedPubMedCentralCrossRefGoogle Scholar
  20. 20.
    Tun HW, Wallace KH, Grinton SF, Khoor A, Burger CD. Etanercept therapy for late-onset idiopathic pneumonia syndrome after nonmyeloablative allogeneic hematopoietic stem cell transplantation. Transplant Proc. 2005;37(10):4492–6.PubMedCrossRefGoogle Scholar
  21. 21.
    Shukla M, Yang S, Milla C, Panoskaltsis-Mortari A, Blazar BR, Haddad IY. Absence of host tumor necrosis factor receptor 1 attenuates manifestations of idiopathic pneumonia syndrome. Am J Physiol Lung Cell Mol Physiol. 2005;288(5):L942–9.PubMedCrossRefGoogle Scholar
  22. 22.
    Afessa B, Tefferi A, Litzow MR, Krowka MJ, Wylam ME, Peters SG. Diffuse alveolar hemorrhage in hematopoietic stem cell transplant recipients. Am J Respir Crit Care Med. 2002;166(5):641–5.PubMedCrossRefGoogle Scholar
  23. 23.
    Jules-Elysee K, Stover DE, Yahalom J, White DA, Gulati SC. Pulmonary complications in lymphoma patients treated with high-dose therapy autologous bone marrow transplantation. Am Rev Respir Dis. 1992;146(2):485–91.PubMedCrossRefGoogle Scholar
  24. 24.
    Majhail NS, Parks K, Defor TE, Weisdorf DJ. Diffuse alveolar hemorrhage and infection-associated alveolar hemorrhage following hematopoietic stem cell transplantation: related and high-risk clinical syndromes. Biol Blood Marrow Transplant. 2006;12(10):1038–46.PubMedCrossRefGoogle Scholar
  25. 25.
    Lewis ID, DeFor T, Weisdorf DJ. Increasing incidence of diffuse alveolar hemorrhage following allogeneic bone marrow transplantation: cryptic etiology and uncertain therapy. Bone Marrow Transplant. 2000;26(5):539–43.PubMedCrossRefGoogle Scholar
  26. 26.
    Vahid B, Marik PE. Pulmonary complications of novel antineoplastic agents for solid tumors. Chest. 2008;133(2):528–38.PubMedCrossRefGoogle Scholar
  27. 27.
    Cooper JA Jr, White DA, Matthay RA. Drug-induced pulmonary disease. Part 1: cytotoxic drugs. Am Rev Respir Dis. 1986;133(2):321–40.PubMedGoogle Scholar
  28. 28.
    Sleijfer S. Bleomycin-induced pneumonitis. Chest. 2001;120(2):617–24.PubMedCrossRefGoogle Scholar
  29. 29.
    Jules-Elysee K, White DA. Bleomycin-induced pulmonary toxicity. Clin Chest Med. 1990;11(1):1–20.PubMedGoogle Scholar
  30. 30.
    Copper JA Jr. Drug-induced lung disease. Adv Intern Med. 1997;42:231–68.PubMedPubMedCentralGoogle Scholar
  31. 31.
    White DA, Orenstein M, Godwin TA, Stover DE. Chemotherapy-associated pulmonary toxic reactions during treatment for breast cancer. Arch Intern Med. 1984;144(5):953–6.PubMedCrossRefPubMedCentralGoogle Scholar
  32. 32.
    White DA, Rankin JA, Stover DE, Gellene RA, Gupta S. Methotrexate pneumonitis. Bronchoalveolar lavage findings suggest an immunologic disorder. Am Rev Respir Dis. 1989;139(1):18–21.PubMedCrossRefPubMedCentralGoogle Scholar
  33. 33.
    Helman DL Jr, Byrd JC, Ales NC, Shorr AF. Fludarabine-related pulmonary toxicity: a distinct clinical entity in chronic lymphoproliferative syndromes. Chest. 2002;122(3):785–90.PubMedCrossRefPubMedCentralGoogle Scholar
  34. 34.
    Trojan A, Meier R, Licht A, Taverna C. Eosinophilic pneumonia after administration of fludarabine for the treatment of non-Hodgkin’s lymphoma. Ann Hematol. 2002;81(9):535–7.PubMedCrossRefPubMedCentralGoogle Scholar
  35. 35.
    Siderov J, Prasad P, De Boer R, Desai J. Safe administration of etoposide phosphate after hypersensitivity reaction to intravenous etoposide. Br J Cancer. 2002;86(1):12–3.PubMedPubMedCentralCrossRefGoogle Scholar
  36. 36.
    Gurjal A, An T, Valdivieso M, Kalemkerian GP. Etoposide-induced pulmonary toxicity. Lung Cancer. 1999;26(2):109–12.PubMedCrossRefPubMedCentralGoogle Scholar
  37. 37.
    Moskowitz CH, Bertino JR, Glassman JR, Hedrick EE, Hunte S, Coady-Lyons N, et al. Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin’s lymphoma. J Clin Oncol. 1999;17(12):3776–85.PubMedCrossRefPubMedCentralGoogle Scholar
  38. 38.
    Di Ianni M, Ballanti S, Iodice G, Reale A, Falzetti F, Minelli O, et al. High-dose thiotepa, etoposide and carboplatin as conditioning regimen for autologous stem cell transplantation in patients with high-risk Hodgkin’s lymphoma. Hematology. 2012;17(1):23–7.PubMedCrossRefPubMedCentralGoogle Scholar
  39. 39.
    Kopterides P, Lignos M, Mentzelopoulos S, Armaganidis A, Pappa V. Cytarabine-induced lung injury: case report. Anticancer Drugs. 2005;16(7):743–5.PubMedCrossRefGoogle Scholar
  40. 40.
    Bergeron A, Rea D, Levy V, Picard C, Meignin V, Tamburini J, et al. Lung abnormalities after dasatinib treatment for chronic myeloid leukemia: a case series. Am J Respir Crit Care Med. 2007;176(8):814–8.PubMedCrossRefPubMedCentralGoogle Scholar
  41. 41.
    Goligher EC, Cserti-Gazdewich C, Balter M, Gupta V, Brandwein JE. Acute lung injury during antithymocyte globulin therapy for aplastic anemia. Can Respir J. 2009;16(2):e3–5.PubMedPubMedCentralCrossRefGoogle Scholar
  42. 42.
    Sirvent-von Bueltzingsloewen A, Gratecos N, Legros L, Fuzibet JG, Cassuto JP. Antithymocyte-associated reticulonodular pneumonitis during a conditioning regimen of reduced intensity for genoidentical bone marrow transplantation. Bone Marrow Transplant. 2001;27(8):891–2.PubMedCrossRefPubMedCentralGoogle Scholar
  43. 43.
    O’Driscoll BR, Hasleton PS, Taylor PM, Poulter LW, Gattameneni HR, Woodcock AA. Active lung fibrosis up to 17 years after chemotherapy with carmustine (BCNU) in childhood. N Engl J Med. 1990;323(6):378–82.PubMedCrossRefPubMedCentralGoogle Scholar
  44. 44.
    Wilczynski SW, Erasmus JJ, Petros WP, Vredenburgh JJ, Folz RJ. Delayed pulmonary toxicity syndrome following high-dose chemotherapy and bone marrow transplantation for breast cancer. Am J Respir Crit Care Med. 1998;157(2):565–73.PubMedCrossRefPubMedCentralGoogle Scholar
  45. 45.
    Oliner H, Schwartz R, Rubio F, Dameshek W. Interstitial pulmonary fibrosis following busulfan therapy. Am J Med. 1961;31:134–9.PubMedCrossRefPubMedCentralGoogle Scholar
  46. 46.
    Heard BE, Cooke RA. Busulphan lung. Thorax. 1968;23(2):187–93.PubMedPubMedCentralCrossRefGoogle Scholar
  47. 47.
    Akasheh MS, Freytes CO, Vesole DH. Melphalan-associated pulmonary toxicity following high-dose therapy with autologous hematopoietic stem cell transplantation. Bone Marrow Transplant. 2000;26(10):1107–9.PubMedCrossRefPubMedCentralGoogle Scholar
  48. 48.
    Malik SW, Myers JL, DeRemee RA, Specks U. Lung toxicity associated with cyclophosphamide use. Two distinct patterns. Am J Respir Crit Care Med. 1996;154(6 Pt 1):1851–6.PubMedCrossRefPubMedCentralGoogle Scholar
  49. 49.
    Hadjinicolaou AV, Nisar MK, Parfrey H, Chilvers ER, Ostor AJ. Non-infectious pulmonary toxicity of rituximab: a systematic review. Rheumatology (Oxford). 2012;51(4):653–62.CrossRefGoogle Scholar
  50. 50.
    White DA, Camus P, Endo M, Escudier B, Calvo E, Akaza H, et al. Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma. Am J Respir Crit Care Med. 2010;182(3):396–403.PubMedCrossRefGoogle Scholar
  51. 51.
    Johnston L, Florek M, Armstrong R, McCune JS, Arai S, Brown J, et al. Sirolimus and mycophenolate mofetil as GVHD prophylaxis in myeloablative, matched-related donor hematopoietic cell transplantation. Bone Marrow Transplant. 2012;47(4):581–8.PubMedCrossRefGoogle Scholar
  52. 52.
    Roberts CM, Foulcher E, Zaunders JJ, Bryant DH, Freund J, Cairns D, et al. Radiation pneumonitis: a possible lymphocyte-mediated hypersensitivity reaction. Ann Intern Med. 1993;118(9):696–700.PubMedCrossRefGoogle Scholar
  53. 53.
    Martin C, Romero S, Sanchez-Paya J, Massuti B, Arriero JM, Hernandez L. Bilateral lymphocytic alveolitis: a common reaction after unilateral thoracic irradiation. Eur Respir J. 1999;13(4):727–32.PubMedCrossRefGoogle Scholar
  54. 54.
    Wojno KJ, Vogelsang GB, Beschorner WE, Santos GW. Pulmonary hemorrhage as a cause of death in allogeneic bone marrow recipients with severe acute graft-versus-host disease. Transplantation. 1994;57(1):88–92.PubMedCrossRefGoogle Scholar
  55. 55.
    Gopal R, Ha CS, Tucker SL, Khouri IF, Giralt SA, Gajewski JL, et al. Comparison of two total body irradiation fractionation regimens with respect to acute and late pulmonary toxicity. Cancer. 2001;92(7):1949–58.PubMedCrossRefGoogle Scholar
  56. 56.
    Cordonnier C, Fleury-Feith J, Escudier E, Atassi K, Bernaudin JF. Secondary alveolar proteinosis is a reversible cause of respiratory failure in leukemic patients. Am J Respir Crit Care Med. 1994;149(3 Pt 1):788–94.PubMedCrossRefGoogle Scholar
  57. 57.
    Tomonari A, Shirafuji N, Iseki T, Ooi J, Nagayama H, Masunaga A, et al. Acquired pulmonary alveolar proteinosis after umbilical cord blood transplantation for acute myeloid leukemia. Am J Hematol. 2002;70(2):154–7.PubMedCrossRefPubMedCentralGoogle Scholar
  58. 58.
    Beccaria M, Luisetti M, Rodi G, Corsico A, Zoia MC, Colato S, et al. Long-term durable benefit after whole lung lavage in pulmonary alveolar proteinosis. Eur Respir J. 2004;23(4):526–31.PubMedCrossRefPubMedCentralGoogle Scholar
  59. 59.
    Tazawa R, Hamano E, Arai T, Ohta H, Ishimoto O, Uchida K, et al. Granulocyte-macrophage colony-stimulating factor and lung immunity in pulmonary alveolar proteinosis. Am J Respir Crit Care Med. 2005;171(10):1142–9.PubMedCrossRefPubMedCentralGoogle Scholar
  60. 60.
    Afessa B, Litzow MR, Tefferi A. Bronchiolitis obliterans and other late onset non-infectious pulmonary complications in hematopoietic stem cell transplantation. Bone Marrow Transplant. 2001;28(5):425–34.PubMedCrossRefGoogle Scholar
  61. 61.
    Maldonado F, Daniels CE, Hoffman EA, Yi ES, Ryu JH. Focal organizing pneumonia on surgical lung biopsy: causes, clinicoradiologic features, and outcomes. Chest. 2007;132(5):1579–83.PubMedCrossRefGoogle Scholar
  62. 62.
    Mokhtari M, Bach PB, Tietjen PA, Stover DE. Bronchiolitis obliterans organizing pneumonia in cancer: a case series. Respir Med. 2002;96(4):280–6.PubMedCrossRefGoogle Scholar
  63. 63.
    Stover DE, Mangino D. Macrolides: a treatment alternative for bronchiolitis obliterans organizing pneumonia? Chest. 2005;128(5):3611–7.PubMedCrossRefGoogle Scholar
  64. 64.
    Papadopoulos EB, Ladanyi M, Emanuel D, Mackinnon S, Boulad F, Carabasi MH, et al. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med. 1994;330(17):1185–91.PubMedCrossRefGoogle Scholar
  65. 65.
    Loren AW, Tsai DE. Post-transplant lymphoproliferative disorder. Clin Chest Med. 2005;26(4):631–45, vii.PubMedCrossRefGoogle Scholar
  66. 66.
    Christie JD, Bavaria JE, Palevsky HI, Litzky L, Blumenthal NP, Kaiser LR, et al. Primary graft failure following lung transplantation. Chest. 1998;114(1):51–60.PubMedCrossRefGoogle Scholar
  67. 67.
    Christie JD, Kotloff RM, Pochettino A, Arcasoy SM, Rosengard BR, Landis JR, et al. Clinical risk factors for primary graft failure following lung transplantation. Chest. 2003;124(4):1232–41.PubMedCrossRefGoogle Scholar
  68. 68.
    Pilcher DV, Snell GI, Scheinkestel CD, Bailey MJ, Williams TJ. High donor age, low donor oxygenation, and high recipient inotrope requirements predict early graft dysfunction in lung transplant recipients. J Heart Lung Transplant. 2005;24(11):1814–20.PubMedCrossRefGoogle Scholar
  69. 69.
    Whitson BA, Nath DS, Johnson AC, Walker AR, Prekker ME, Radosevich DM, et al. Risk factors for primary graft dysfunction after lung transplantation. J Thorac Cardiovasc Surg. 2006;131(1):73–80.PubMedCrossRefGoogle Scholar
  70. 70.
    Thabut G, Mal H, Cerrina J, Dartevelle P, Dromer C, Velly JF, et al. Graft ischemic time and outcome of lung transplantation: a multicenter analysis. Am J Respir Crit Care Med. 2005;171(7):786–91.PubMedCrossRefPubMedCentralGoogle Scholar
  71. 71.
    Kawut SM, Lederer DJ, Keshavjee S, Wilt JS, Daly T, D’Ovidio F, et al. Outcomes after lung retransplantation in the modern era. Am J Respir Crit Care Med. 2008;177(1):114–20.PubMedCrossRefPubMedCentralGoogle Scholar
  72. 72.
    Daud SA, Yusen RD, Meyers BF, Chakinala MM, Walter MJ, Aloush AA, et al. Impact of immediate primary lung allograft dysfunction on bronchiolitis obliterans syndrome. Am J Respir Crit Care Med. 2007;175(5):507–13.PubMedCrossRefPubMedCentralGoogle Scholar
  73. 73.
    Choi JK, Kearns J, Palevsky HI, Montone KT, Kaiser LR, Zmijewski CM, et al. Hyperacute rejection of a pulmonary allograft. Immediate clinical and pathologic findings. Am J Respir Crit Care Med. 1999;160(3):1015–8.PubMedCrossRefPubMedCentralGoogle Scholar
  74. 74.
    Bittner HB, Dunitz J, Hertz M, Bolman MR 3rd, Park SJ. Hyperacute rejection in single lung transplantation--case report of successful management by means of plasmapheresis and antithymocyte globulin treatment. Transplantation. 2001;71(5):649–51.PubMedCrossRefPubMedCentralGoogle Scholar
  75. 75.
    Camargo J, Camargo S, Schio SM, Machuca TN, Perin FA. Hyperacute rejection after single lung transplantation: a case report. Transplant Proc. 2008;40:867–9.CrossRefGoogle Scholar
  76. 76.
    Hopkins PM, Aboyoun CL, Chhajed PN, Malouf MA, Plit ML, Rainer SP, et al. Prospective analysis of 1,235 transbronchial lung biopsies in lung transplant recipients. J Heart Lung Transplant. 2002;21(10):1062–7.PubMedCrossRefPubMedCentralGoogle Scholar
  77. 77.
    Trulock EP. Lung transplantation. Am J Respir Crit Care Med. 1997;155(3):789–818.PubMedCrossRefPubMedCentralGoogle Scholar
  78. 78.
    Glanville AR. Antibody-mediated rejection in lung transplantation: myth or reality? J Heart Lung Transplant. 2010;29(4):395–400.PubMedCrossRefPubMedCentralGoogle Scholar
  79. 79.
    Astor TL, Weill D, Cool C, Teitelbaum I, Schwarz MI, Zamora MR. Pulmonary capillaritis in lung transplant recipients: treatment and effect on allograft function. J Heart Lung Transplant. 2005;24(12):2091–7.PubMedCrossRefPubMedCentralGoogle Scholar
  80. 80.
    Morgans AK, Reshef R, Tsai DE. Posttransplant lymphoproliferative disorder following kidney transplant. Am J Kidney Dis. 2010;55(1):168–80.PubMedCrossRefPubMedCentralGoogle Scholar
  81. 81.
    Ibrahim HA, Naresh KN. Posttransplant lymphoproliferative disorders. Adv Hematol. 2012;2012:230173.PubMedPubMedCentralCrossRefGoogle Scholar
  82. 82.
    Dharnidharka VR, Lamb KE, Gregg JA, Meier-Kriesche HU. Associations between EBV serostatus and organ transplant type in PTLD risk: an analysis of the SRTR National Registry Data in the United States. Am J Transplant. 2012;12(4):976–83.PubMedCrossRefPubMedCentralGoogle Scholar
  83. 83.
    Kremer BE, Reshef R, Misleh JG, Christie JD, Ahya VN, Blumenthal NP, et al. Post-transplant lymphoproliferative disorder after lung transplantation: a review of 35 cases. J Heart Lung Transplant. 2012;31(3):296–304.PubMedCrossRefPubMedCentralGoogle Scholar
  84. 84.
    Borhani AA, Hosseinzadeh K, Almusa O, Furlan A, Nalesnik M. Imaging of posttransplantation lymphoproliferative disorder after solid organ transplantation. Radiographics. 2009;29(4):981–1000. discussion -2.PubMedCrossRefPubMedCentralGoogle Scholar
  85. 85.
    Allen U, Preiksaitis J, Practice ASTIDCo. Epstein-barr virus and posttransplant lymphoproliferative disorder in solid organ transplant recipients. Am J Transplant. 2009;9(Suppl 4):S87–96.PubMedCrossRefPubMedCentralGoogle Scholar
  86. 86.
    Gulley ML, Tang W. Using Epstein-Barr viral load assays to diagnose, monitor, and prevent posttransplant lymphoproliferative disorder. Clin Microbiol Rev. 2010;23(2):350–66.PubMedPubMedCentralCrossRefGoogle Scholar
  87. 87.
    Tsai DE, Hardy CL, Tomaszewski JE, Kotloff RM, Oltoff KM, Somer BG, et al. Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: analysis of prognostic variables and long-term follow-up of 42 adult patients. Transplantation. 2001;71(8):1076–88.PubMedCrossRefPubMedCentralGoogle Scholar
  88. 88.
    Evens AM, David KA, Helenowski I, Nelson B, Kaufman D, Kircher SM, et al. Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era. J Clin Oncol. 2010;28(6):1038–46.PubMedPubMedCentralCrossRefGoogle Scholar
  89. 89.
    Elstrom RL, Andreadis C, Aqui NA, Ahya VN, Bloom RD, Brozena SC, et al. Treatment of PTLD with rituximab or chemotherapy. Am J Transplant. 2006;6(3):569–76.PubMedCrossRefPubMedCentralGoogle Scholar
  90. 90.
    Bellil Y, Edelman MJ. Bronchogenic carcinoma in solid organ transplant recipients. Curr Treat Options Oncol. 2006;7(1):77–81.PubMedCrossRefGoogle Scholar
  91. 91.
    Dickson RP, Davis RD, Rea JB, Palmer SM. High frequency of bronchogenic carcinoma after single-lung transplantation. J Heart Lung Transplant. 2006;25(11):1297–301.PubMedPubMedCentralCrossRefGoogle Scholar
  92. 92.
    Champion L, Stern M, Israel-Biet D, Mamzer-Bruneel MF, Peraldi MN, Kreis H, et al. Brief communication: sirolimus-associated pneumonitis: 24 cases in renal transplant recipients. Ann Intern Med. 2006;144(7):505–9.PubMedCrossRefGoogle Scholar
  93. 93.
    Lee HS, Huh KH, Kim YS, Kim MS, Kim HJ, Kim SI, et al. Sirolimus-induced pneumonitis after renal transplantation: a single-center experience. Transplant Proc. 2012;44(1):161–3.PubMedCrossRefGoogle Scholar
  94. 94.
    Garrean S, Massad MG, Tshibaka M, Hanhan Z, Caines AE, Benedetti E. Sirolimus-associated interstitial pneumonitis in solid organ transplant recipients. Clin Transpl. 2005;19(5):698–703.CrossRefGoogle Scholar
  95. 95.
    Chau EM, Chow WH. Sirolimus-induced pneumonitis presenting as acute respiratory distress syndrome. J Heart Lung Transplant. 2006;25(7):867–8.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Robert M. Kotloff
    • 1
  • Burton F. Dickey
    • 2
  • Nicholas Vander Els
    • 3
    Email author
  1. 1.Department of Pulmonary MedicineRespiratory Institute, Cleveland ClinicClevelandUSA
  2. 2.Department of Pulmonary MedicineUniversity of Texas MD Anderson Cancer CenterHoustonUSA
  3. 3.Pulmonary Service, Memorial Sloan- Kettering Cancer CenterNew YorkUSA

Personalised recommendations